Pioneering Experts

Who We Are

FibroBiologics is the leading biopharmaceutical company focused on developing and commercializing fibroblast cell-based therapies for patients suffering from chronic diseases.

Our proprietary fibroblast platform serves as the foundation for developing biologic cures and treatments for chronic diseases, including degenerative disc disease, multiple sclerosis, wound healing, and cancer, and anti-aging extension of life applications such as thymic involution reversal and splenic involution reversal.

Currently, FibroBiologics holds 150+ U.S. and International issued/pending patents across a variety of clinical pathways, including multiple sclerosis, cartilage repair, degenerative disc, cancer, wound healing, and extension of life programs. 

FibroBiologics is leading the next generation of medical advancement in fibroblast cell-based therapies.

How We Came to Be ...

After Shinya Yamanaka, Ph.D. won the Nobel Prize in 2012 for his work with induced pluripotent stem cells, the discovery race for stem cell advancement spread around the world.  As break-throughs in the lab led to first-in-human trials for stem cells, our Founder, Pete O’Heeron recognized the potential therapeutic benefits of fibroblasts and began to develop the science around this “new” cell source.  Fibroblasts, one of the most abundant cells in the human body and present in all tissues and systems, have demonstrated similar characteristics as stem cells, but appear to be a  better cell source due to their potency and ease of use1, 2.

Challenging our scientists to explore the “edge of the envelope” for clinical applications, we discovered that fibroblasts seem to be involved in many of the body’s biological processes. The potential curative benefits of fibroblasts seem almost endless and our company is dedicated to achieving cures for chronic diseases and regenerative medicine using this unique, potent and abundant cell source.

Fibroblasts continue to show great promise and potential for the future

FibroBiologics was founded 2 years ago to deliver on that promise and harness the potential power of fibroblast cell-based therapies for patients, everywhere.

From research to medicine, FibroBiologics is fundamentally changing the treatment paradigm for chronic diseases by introducing biologic treatments and potential cures to the world.

“People who are crazy enough to change the world are the ones that do.”

–Steve Jobs

Leadership

Pete O’Heeron

Chairman/Founder/CEO

Mark Andersen, CFA

Chief Financial Officer

Hamid Khoja, Ph.D.

Chief Scientific Officer

Ruben Garcia, JD

General Counsel

Board of Directors

Pete O’Heeron

Chairman/Founder/CEO

Stacy Coen

Board of Directors

Robert E. Hoffman

Board of Directors

Matt Link

Board of Directors

Victoria Niklas, M.D.

Board of Directors

Richard C. Cilento, Jr.

Board of Directors

Scientific Advisory Board

Claudia Lucchinetti, M.D.

Scientific Advisory Board

S. Thomas Carmichael, M.D., Ph.D.

Scientific Advisory Board

Kate Rubins, Ph.D.

Scientific Advisory Board

Elizabeth Shpall, M.D.

Scientific Advisory Board

Neil Bhowmick, Ph.D.

Scientific Advisory Board

See What’s in the
FibroBiologics Pipeline